JPS6256128B2 - - Google Patents
Info
- Publication number
- JPS6256128B2 JPS6256128B2 JP54057690A JP5769079A JPS6256128B2 JP S6256128 B2 JPS6256128 B2 JP S6256128B2 JP 54057690 A JP54057690 A JP 54057690A JP 5769079 A JP5769079 A JP 5769079A JP S6256128 B2 JPS6256128 B2 JP S6256128B2
- Authority
- JP
- Japan
- Prior art keywords
- pharmacologically active
- suppository
- fatty acid
- sodium
- salts
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- -1 alkali metal salt Chemical class 0.000 claims description 39
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 35
- 229930195729 fatty acid Natural products 0.000 claims description 35
- 239000000194 fatty acid Substances 0.000 claims description 35
- 239000013543 active substance Substances 0.000 claims description 28
- 239000000203 mixture Substances 0.000 claims description 26
- 150000004665 fatty acids Chemical class 0.000 claims description 22
- 229910052783 alkali metal Inorganic materials 0.000 claims description 18
- 125000004432 carbon atom Chemical group C* 0.000 claims description 16
- 239000002585 base Substances 0.000 claims description 14
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 10
- 159000000000 sodium salts Chemical class 0.000 claims description 7
- 102000004877 Insulin Human genes 0.000 claims description 5
- 108090001061 Insulin Proteins 0.000 claims description 5
- 229940125396 insulin Drugs 0.000 claims description 5
- 150000001875 compounds Chemical class 0.000 claims description 4
- 125000003460 beta-lactamyl group Chemical group 0.000 claims 1
- 239000000829 suppository Substances 0.000 description 28
- 210000004369 blood Anatomy 0.000 description 18
- 239000008280 blood Substances 0.000 description 18
- MLYYVTUWGNIJIB-BXKDBHETSA-N cefazolin Chemical compound S1C(C)=NN=C1SCC1=C(C(O)=O)N2C(=O)[C@@H](NC(=O)CN3N=NN=C3)[C@H]2SC1 MLYYVTUWGNIJIB-BXKDBHETSA-N 0.000 description 15
- 229960001139 cefazolin Drugs 0.000 description 15
- 238000000034 method Methods 0.000 description 13
- 238000002360 preparation method Methods 0.000 description 10
- 238000003756 stirring Methods 0.000 description 10
- 239000011734 sodium Substances 0.000 description 9
- 238000010521 absorption reaction Methods 0.000 description 8
- 238000009472 formulation Methods 0.000 description 8
- 239000006215 rectal suppository Substances 0.000 description 7
- 150000003839 salts Chemical class 0.000 description 7
- 229930186147 Cephalosporin Natural products 0.000 description 6
- 229930182555 Penicillin Natural products 0.000 description 6
- 210000000436 anus Anatomy 0.000 description 6
- 229940124587 cephalosporin Drugs 0.000 description 6
- 150000001780 cephalosporins Chemical class 0.000 description 6
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical class CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 229910052708 sodium Inorganic materials 0.000 description 6
- FIWQZURFGYXCEO-UHFFFAOYSA-M sodium;decanoate Chemical compound [Na+].CCCCCCCCCC([O-])=O FIWQZURFGYXCEO-UHFFFAOYSA-M 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 210000002700 urine Anatomy 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 5
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 5
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical class CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 238000000691 measurement method Methods 0.000 description 5
- 239000000693 micelle Substances 0.000 description 5
- 150000002960 penicillins Chemical class 0.000 description 5
- 210000000664 rectum Anatomy 0.000 description 5
- 239000002511 suppository base Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 235000014469 Bacillus subtilis Nutrition 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 229960000723 ampicillin Drugs 0.000 description 4
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 4
- 239000003242 anti bacterial agent Substances 0.000 description 4
- 229940088710 antibiotic agent Drugs 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 238000007918 intramuscular administration Methods 0.000 description 4
- 159000000001 potassium salts Chemical class 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 229940100618 rectal suppository Drugs 0.000 description 4
- JAJWGJBVLPIOOH-IZYKLYLVSA-M sodium taurocholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 JAJWGJBVLPIOOH-IZYKLYLVSA-M 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 241000282472 Canis lupus familiaris Species 0.000 description 3
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 description 3
- 241000191938 Micrococcus luteus Species 0.000 description 3
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 3
- 238000004166 bioassay Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 210000004731 jugular vein Anatomy 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- 230000008018 melting Effects 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- RPACBEVZENYWOL-XFULWGLBSA-M sodium;(2r)-2-[6-(4-chlorophenoxy)hexyl]oxirane-2-carboxylate Chemical compound [Na+].C=1C=C(Cl)C=CC=1OCCCCCC[C@]1(C(=O)[O-])CO1 RPACBEVZENYWOL-XFULWGLBSA-M 0.000 description 3
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 2
- RZRNAYUHWVFMIP-QJRAZLAKSA-N 1-oleoyl-sn-glycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)CO RZRNAYUHWVFMIP-QJRAZLAKSA-N 0.000 description 2
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 2
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- RMMXTBMQSGEXHJ-UHFFFAOYSA-N Aminophenazone Chemical compound O=C1C(N(C)C)=C(C)N(C)N1C1=CC=CC=C1 RMMXTBMQSGEXHJ-UHFFFAOYSA-N 0.000 description 2
- 239000005639 Lauric acid Substances 0.000 description 2
- 239000005642 Oleic acid Substances 0.000 description 2
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 125000000066 S-methyl group Chemical group [H]C([H])([H])S* 0.000 description 2
- BCKXLBQYZLBQEK-KVVVOXFISA-M Sodium oleate Chemical compound [Na+].CCCCCCCC\C=C/CCCCCCCC([O-])=O BCKXLBQYZLBQEK-KVVVOXFISA-M 0.000 description 2
- 229960000212 aminophenazone Drugs 0.000 description 2
- KLOHDWPABZXLGI-YWUHCJSESA-M ampicillin sodium Chemical compound [Na+].C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C([O-])=O)(C)C)=CC=CC=C1 KLOHDWPABZXLGI-YWUHCJSESA-M 0.000 description 2
- 229960001931 ampicillin sodium Drugs 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 150000001735 carboxylic acids Chemical class 0.000 description 2
- 125000005534 decanoate group Chemical class 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- FBUKVWPVBMHYJY-UHFFFAOYSA-N nonanoic acid Chemical class CCCCCCCCC(O)=O FBUKVWPVBMHYJY-UHFFFAOYSA-N 0.000 description 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical class CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 229960002292 piperacillin Drugs 0.000 description 2
- WCMIIGXFCMNQDS-IDYPWDAWSA-M piperacillin sodium Chemical compound [Na+].O=C1C(=O)N(CC)CCN1C(=O)N[C@H](C=1C=CC=CC=1)C(=O)N[C@@H]1C(=O)N2[C@@H](C([O-])=O)C(C)(C)S[C@@H]21 WCMIIGXFCMNQDS-IDYPWDAWSA-M 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 239000012266 salt solution Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 230000036325 urinary excretion Effects 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- WRFCGBVLTRJBKN-QSNWEANLSA-N (2s,5r,6r)-6-[[(2r)-2-[[2-[[amino(pyridin-4-yl)methylidene]amino]acetyl]amino]-2-phenylacetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid Chemical compound N([C@@H](C(=O)N[C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C=1C=CC=CC=1)C(=O)CN=C(N)C1=CC=NC=C1 WRFCGBVLTRJBKN-QSNWEANLSA-N 0.000 description 1
- OKBVVJOGVLARMR-QMTHXVAHSA-N (6R,7R)-7-[[2-(2-amino-4-thiazolyl)-2-(carboxymethoxyimino)-1-oxoethyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound S1C(N)=NC(C(=NOCC(O)=O)C(=O)N[C@@H]2C(N3C(=C(C=C)CS[C@@H]32)C(O)=O)=O)=C1 OKBVVJOGVLARMR-QMTHXVAHSA-N 0.000 description 1
- WKJGTOYAEQDNIA-IOOZKYRYSA-N (6r,7r)-7-[[(2r)-2-amino-2-phenylacetyl]amino]-3-chloro-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid;hydrate Chemical compound O.C1([C@H](C(=O)N[C@@H]2C(N3C(=C(Cl)CS[C@@H]32)C(O)=O)=O)N)=CC=CC=C1 WKJGTOYAEQDNIA-IOOZKYRYSA-N 0.000 description 1
- ILPBINAXDRFYPL-UHFFFAOYSA-N 2-octene Chemical compound CCCCCC=CC ILPBINAXDRFYPL-UHFFFAOYSA-N 0.000 description 1
- NNYHKYDYHWSHKQ-UHFFFAOYSA-N 4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid Chemical compound OC(=O)C1CSC2CCN12 NNYHKYDYHWSHKQ-UHFFFAOYSA-N 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 description 1
- NCFTXMQPRQZFMZ-WERGMSTESA-M Cefoperazone sodium Chemical compound [Na+].O=C1C(=O)N(CC)CCN1C(=O)N[C@H](C=1C=CC(O)=CC=1)C(=O)N[C@@H]1C(=O)N2C(C([O-])=O)=C(CSC=3N(N=NN=3)C)CS[C@@H]21 NCFTXMQPRQZFMZ-WERGMSTESA-M 0.000 description 1
- GNWUOVJNSFPWDD-XMZRARIVSA-M Cefoxitin sodium Chemical compound [Na+].N([C@]1(OC)C(N2C(=C(COC(N)=O)CS[C@@H]21)C([O-])=O)=O)C(=O)CC1=CC=CS1 GNWUOVJNSFPWDD-XMZRARIVSA-M 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010060891 General symptom Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010015776 Glucose oxidase Proteins 0.000 description 1
- 239000004366 Glucose oxidase Substances 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000283977 Oryctolagus Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 239000005643 Pelargonic acid Substances 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 235000009470 Theobroma cacao Nutrition 0.000 description 1
- 229940006249 acetaminophen 100 mg Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000003782 beta lactam antibiotic agent Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- FPPNZSSZRUTDAP-UWFZAAFLSA-N carbenicillin Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)C(C(O)=O)C1=CC=CC=C1 FPPNZSSZRUTDAP-UWFZAAFLSA-N 0.000 description 1
- 229960003669 carbenicillin Drugs 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- RRYMAQUWDLIUPV-BXKDBHETSA-N cefacetrile Chemical compound S1CC(COC(=O)C)=C(C(O)=O)N2C(=O)[C@@H](NC(=O)CC#N)[C@@H]12 RRYMAQUWDLIUPV-BXKDBHETSA-N 0.000 description 1
- 229960004841 cefadroxil Drugs 0.000 description 1
- NBFNMSULHIODTC-CYJZLJNKSA-N cefadroxil monohydrate Chemical compound O.C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=C(O)C=C1 NBFNMSULHIODTC-CYJZLJNKSA-N 0.000 description 1
- FUBBGQLTSCSAON-PBFPGSCMSA-N cefaloglycin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)COC(=O)C)C(O)=O)=CC=CC=C1 FUBBGQLTSCSAON-PBFPGSCMSA-N 0.000 description 1
- 229950004030 cefaloglycin Drugs 0.000 description 1
- 229960000603 cefalotin Drugs 0.000 description 1
- GCFBRXLSHGKWDP-XCGNWRKASA-N cefoperazone Chemical compound O=C1C(=O)N(CC)CCN1C(=O)N[C@H](C=1C=CC(O)=CC=1)C(=O)N[C@@H]1C(=O)N2C(C(O)=O)=C(CSC=3N(N=NN=3)C)CS[C@@H]21 GCFBRXLSHGKWDP-XCGNWRKASA-N 0.000 description 1
- 229960004682 cefoperazone Drugs 0.000 description 1
- 229960002682 cefoxitin Drugs 0.000 description 1
- JFPVXVDWJQMJEE-IZRZKJBUSA-N cefuroxime Chemical compound N([C@@H]1C(N2C(=C(COC(N)=O)CS[C@@H]21)C(O)=O)=O)C(=O)\C(=N/OC)C1=CC=CO1 JFPVXVDWJQMJEE-IZRZKJBUSA-N 0.000 description 1
- 229960001668 cefuroxime Drugs 0.000 description 1
- VUFGUVLLDPOSBC-XRZFDKQNSA-M cephalothin sodium Chemical compound [Na+].N([C@H]1[C@@H]2N(C1=O)C(=C(CS2)COC(=O)C)C([O-])=O)C(=O)CC1=CC=CS1 VUFGUVLLDPOSBC-XRZFDKQNSA-M 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- LQOLIRLGBULYKD-JKIFEVAISA-N cloxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=CC=CC=C1Cl LQOLIRLGBULYKD-JKIFEVAISA-N 0.000 description 1
- 229960003326 cloxacillin Drugs 0.000 description 1
- 208000006111 contracture Diseases 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 238000010227 cup method (microbiological evaluation) Methods 0.000 description 1
- HGBLNBBNRORJKI-WCABBAIRSA-N cyclacillin Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)C1(N)CCCCC1 HGBLNBBNRORJKI-WCABBAIRSA-N 0.000 description 1
- 229960004244 cyclacillin Drugs 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 229960001193 diclofenac sodium Drugs 0.000 description 1
- 102000038379 digestive enzymes Human genes 0.000 description 1
- 108091007734 digestive enzymes Proteins 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229940116332 glucose oxidase Drugs 0.000 description 1
- 235000019420 glucose oxidase Nutrition 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 150000002314 glycerols Chemical class 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 229940082061 indomethacin 25 mg Drugs 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 150000003951 lactams Chemical group 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 231100000017 mucous membrane irritation Toxicity 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 229960002446 octanoic acid Drugs 0.000 description 1
- 235000014593 oils and fats Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 125000006353 oxyethylene group Chemical group 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 235000019371 penicillin G benzathine Nutrition 0.000 description 1
- 229940056360 penicillin g Drugs 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229950004791 pirbenicillin Drugs 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229960005480 sodium caprylate Drugs 0.000 description 1
- BYKRNSHANADUFY-UHFFFAOYSA-M sodium octanoate Chemical compound [Na+].CCCCCCCC([O-])=O BYKRNSHANADUFY-UHFFFAOYSA-M 0.000 description 1
- JGMJQSFLQWGYMQ-UHFFFAOYSA-M sodium;2,6-dichloro-n-phenylaniline;acetate Chemical compound [Na+].CC([O-])=O.ClC1=CC=CC(Cl)=C1NC1=CC=CC=C1 JGMJQSFLQWGYMQ-UHFFFAOYSA-M 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- OHKOGUYZJXTSFX-KZFFXBSXSA-N ticarcillin Chemical compound C=1([C@@H](C(O)=O)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)C=CSC=1 OHKOGUYZJXTSFX-KZFFXBSXSA-N 0.000 description 1
- 229960004659 ticarcillin Drugs 0.000 description 1
- 239000003106 tissue adhesive Substances 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000002132 β-lactam antibiotic Substances 0.000 description 1
- 229940124586 β-lactam antibiotics Drugs 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Description
æ¬çºæã¯ãçŽè
žæäžçšçµæç©ã«é¢ãããããã«
詳ããã¯ãæ¬çºæã¯ãè¬ç掻æ§ç©è³ªã®ãçŽè žãã
ã®åžåãæ¹åãããçŽè žæäžçšçµæç©ã«é¢ããã çµå£æäžã«ããè¡äžãžã®åžåã®å°é£ãªè¬ç掻æ§
ç©è³ªã¯ãäžè¬ã«æ³šå°ã«ãã€ãŠæäžããŠããããã
ããªãã泚å°ã®å Žåã¯ãçŒçã䌎ã䜿çšã«éããŠ
䟿å®çã§ãªãããã€çæçž®çãªã©ã®å±éºæ§ãªã©ã
䌎ããå¿ ãããæºè¶³ã®ãããã®ã§ã¯ãªãããŸãæ
çç©è³ªäžã®æ¯èŒçåžåæ§ã®ããè¬ç掻æ§ç©è³ªãçµ
å£æäžããå Žåããè¡äžæ¿åºŠã極ããŠçæéã®ã
ã¡ã«äœæžããããæäžéãå¢ãããããããã¯æ
äžåæ°ãå€ãããªããã°ãªããããã®éçããæª
åžååã«ãã€ãŠè žå åžžåšèã殺èãããã¯éèã
ãããã®çµæè žå èå¢ã®å€è²ãã¿ãèšåºäžå¥œãŸã
ããªãåé¡ãæ¹èµ·ããŠãããããã«ã¯ãçµå£æäž
ã«ãã€ãŠã¯æ¶å管å ã«ãããŠæ¶åé µçŽ ã«ãã€ãŠå
解ãããååç©ãå€ãç¥ãããŠããã ãããå®æ ãããçäœå ã«è¯å¥œã«è¬ç掻æ§ç©è³ª
ãåžåãããããã«ãçš®ã ã®è©Šã¿ããªãããŠã
ããç¹ã«çŽè žå æäžã«ããè©Šã¿ãå€ãã ããããªãããåŸæ¥ç¥ãããŠããçŽè žæäžçšçµ
æç©ã¯ãåžåãäžååã§ãã€ãããå®å šæ§ã®ç¹ã§
æºè¶³ã®ãããã®ã§ãªãã€ããã極ããŠç¹å®ããã
è¬ç掻æ§ç©è³ªã«ã€ããŠããåžåä¿é²å¹æã瀺ããª
ãã€ããããããã¯çŽè žç²èåºæ¿äœçšãæããã
ã§ãå¿ ãããæºè¶³ã®ãããã®ã§ã¯ãªããç¹ã«ãã
ãã·ãªã³é¡ãã»ãã¢ãã¹ããªã³é¡ã®ãããªÎ²âã©
ã¯ã¿ã ååç©ãã€ã³ã·ãŠãªã³ãªã©ã®é«ååããã¿
ã€ãã¯ãããèªäœã§ã¯çŽè žããåžåãããããã
ãã®çŽè žæäžè£œå€ã®éçºã®è©Šã¿ããªãããŠãã
ããããããæºè¶³ã®ãããã®ã§ã¯ãªãã æ¬çºæè ãã¯ããã®ãããªå®æ ã«éã¿ãŠéæç
究ãéããçµæãççŽ æ°ïŒã12ã®èèªé žã®ã¢ã«ã«
ãªéå±å¡©ãããã»ã«ã圢æããŠããªãå Žåã«æ¥µã
ãŠåºæ±ãªè¬ç掻æ§ç©è³ªã«å¯ŸããŠãç¹ã«ãããã·ãª
ã³é¡ãã»ãã¢ãã¹ããªã³é¡ã®åŠãβâã©ã¯ã¿ã å
åç©ãã€ã³ã·ãŠãªã³ãªã©ã®é«ååããã¿ã€ãã«ã€
ããŠããçŽè žããã®è¡äžãžã®åžåä¿é²å¹æã瀺ã
ããšãèŠåºããããã«æ€èšãéããçµæãæ¬çºæ
ãå®æããã«è³ã€ãã å³ã¡ãæ¬çºæã¯ãççŽ æ°ïŒä¹è³12ã®èèªé žã®ã¢
ã«ã«ãªéå±å¡©ãæ²¹æ§åºå€äžã«åæ£ç¶æ ã§å«æãã
ãŠãªãããšãç¹åŸŽãšããéãã»ã«åçŽè žæäžçšçµ
æç©ã§ããã æ¬çºæã§äœ¿çšãããççŽ æ°ïŒã12ã®èèªé žã®ã¢
ã«ã«ãªéå±å¡©ã¯å€©ç¶ç±æ¥ã®ãã®ã§ããåæç±æ¥ã®
ãã®ã§ããããã奜é©ã«ã¯å€©ç¶ç±æ¥ã®ãã®ã䜿çš
ãããã該èèªé žå¡©ãšããŠã¯ãçŽéç¶ãåå²ç¶ã®
äž¡è ãããããã奜ãŸããã¯çŽéç¶ã®ãã®ããã
ãããã ãããèèªé žã®ã¢ã«ã«ãªéå±å¡©ãšããŠã¯ãããš
ãã°ãã«ããªã³é žå¡©ãã©ãŠãªã³é žå¡©ãªã©ãããã«
奜é©ã«ã¯ãã«ããªã³é žå¡©ããããããã æ¬çºæã§ããççŽ æ°ïŒã12ã®èèªé žã®ã¢ã«ã«ãª
éå±å¡©ãšããŠã¯ãããšãã°ãããªãŠã å¡©ãã«ãªãŠ
ã å¡©ãªã©ããããããã 該èèªé žã®ã¢ã«ã«ãªéå±å¡©ãšããŠã¯ãå ·äœçã«
ã¯ãããšãã°ã«ããªã«é žã®ãããªãŠã å¡©ããã³ã«
ãªãŠã å¡©ïŒãã©ã«ãŽã³é žã®ãããªãŠã å¡©ïŒã«ããª
ã³é žã®ãããªãŠã å¡©ããã³ã«ãªãŠã å¡©ïŒã©ãŠãªã³
é žã®ãããªãŠã å¡©ããã³ã«ãªãŠã å¡©ãªã©ãããã
ããããããã®ã®ãã¡ãäžè¿°ã®ã«ããªã³é žã®å¡©ã
ã©ãŠãªã³é žã®å¡©ã奜é©ã§ããã ããã«å¥œãŸããã¯ãã«ããªã³é žã®å¡©ããããã
ãã ãããççŽ æ°ïŒã12ã®èèªé žã®ã¢ã«ã«ãªéå±å¡©
ã¯åç¬ã§äœ¿çšããŠããããããŸãã¯äºçš®ä»¥äžãçµ
åãããŠäœ¿çšããŠãããã ãã®ççŽ æ°ïŒã12ã®èèªé žã®ã¢ã«ã«ãªéå±å¡©ã®
䜿çšéã¯ãéåžžãå šè£œå€äž0.5ã20ïŒ ã奜ãŸãã
ã¯ïŒã15ïŒ ãããã«å¥œãŸããã¯ïŒã10ïŒ ã§ããã æ¬çºæã§ããè¬ç掻æ§ç©è³ªã¯ãè¡äžã«åžåãã
ãŠè¬å¹ãçºæ®ãããã®ã§ããã°ããããã§ãã
ããç¹ã«ãçµå£æäžãçŽè žæäžã«ãã€ãŠåžåãã
ããåŸæ¥æ³šå°ã«ãã€ãŠã®ã¿æäžãããŠãããã®ã§
ããæ¬çºæã®çµæç©ã䜿çšããããšã«ãã€ãŠãçŽ
è žãã容æã«åžåãããããšã«ãªãã®ã§ããã®ã
ããªé£åžåæ§ã®è¬ç掻æ§ç©è³ªã«å¯ŸããŠãæ¬çºæã®
çŽè žæäžçšçµæç©ã䜿çšããããšã®æ矩ãããã
è¬ç掻æ§ç©è³ªãšããŠã¯ãå ·äœçã«ã¯ãããšãã°Î²
âã©ã¯ã¿ã ç°ãæããååç©ïŒããšãã°ãããã·
ãªã³é¡ãã»ãã¢ãã¹ããªã³é¡ãªã©ïŒãããã¿ã€ã
ç³»ååç©ãªã©ãããããããããã·ãªã³é¡ãšããŠ
ã¯ãããšãã°ã¢ã³ãã·ãªã³ãã·ã¯ã©ã·ãªã³ãã¯ã
ããµã·ãªã³ããã³ãžã«ããã·ãªã³ãã«ã«ããã·ãª
ã³ãããã©ã·ãªã³ãã¡ãŸãã·ãªã³ããã«ããã·ãª
ã³ããã«ã«ã·ãªã³ãïŒ2Sã»5Rã»6RïŒâïŒâãïŒïŒ²ïŒ
âïŒâïŒïŒâãã€ãããªãã·âïŒã»ïŒâããããª
ãžã³âïŒâã«ã«ãããµã¢ããïŒâïŒâããšãã«ã¢
ã»ãã¢ãããâïŒã»ïŒâãžã¡ãã«âïŒâãªããœâ
ïŒâãã¢âïŒâã¢ã¶ãã·ã¯ããïŒã»ïŒã»ïŒããã
ã¿ã³âïŒâã«ã«ãã³é žããã³ãã®ãããªãŠã å¡©ç
ã®å¡©ãªã©ããããããã ã»ãã¢ãã¹ããªã³é¡ãšããŠã¯ããšãã°ã»ãã¢ã
ãã³ãã»ããã·ãã³ãã»ãã¢ãŸãªã³ãã»ãã¢ããª
ãžã³ãã»ãã¢ã»ããªã«ãã»ãã¢ãã¢ã ãã»ããªã©
ãããã»ãã¢ãã³ãã»ãã¢ã¯ããŒã«ãã»ãã¢ãã
ãã·ã«ãã»ãã¢ããªãžã³ãã»ãã©ãžã³ãã»ãã¢ã
ã°ãªã·ã³ãïŒâãïŒâïŒâαâïŒïŒâãšãã«â
ïŒã»ïŒâãžãªããœâïŒâããã©ãžã³âã«ã«ãããµ
ããïŒâαâïŒïŒâããããã·ããšãã«ïŒã¢ã»ã¿ã
ããâïŒâãïŒïŒâã¡ãã«â1Hâããã©ãŸãŒã«âïŒ
âã€ã«ïŒããªã¡ãã«ãâïŒâã»ãã¢ã âïŒâã«ã«
ãã³é žïŒä»¥äžãâ1551ãšç¥ç§°ããïŒãïŒ6Rã»
7RïŒâãïŒïŒºïŒâïŒâã¡ããã·ã€ããâïŒâïŒïŒâã€
ããâïŒâãã¢ãŸãªã³âïŒâã€ã«ïŒâã¢ã»ã¿ã
ããâïŒâãªããœâïŒâãã¢âïŒâã¢ã¶ãã·ã¯ã
ãïŒã»ïŒã»ïŒããªã¯ãâïŒâãšã³âïŒâã«ã«ãã³
é žãïŒ6Rã»7RïŒâïŒâãïŒâã«ã«ããã·âïŒâïŒïŒ
âããããã·ããšãã«ïŒã¢ã»ã¿ãããâïŒâã¡ã
ãã·âïŒâãïŒïŒâã¡ãã«â1Hâããã©ãŸãŒã«â
ïŒâã€ã«âããªïŒã¡ãã«ãâïŒâãªããœâïŒâãª
ããµâïŒâã¢ã¶ãã·ã¯ããïŒã»ïŒã»ïŒããªã¯ã¿â
ïŒâãšã³ïŒâã«ã«ãã³é žãïŒÎ²âãïŒâïŒïŒâã¢ã
ããã¢ãŸãŒã«âïŒâã€ã«ïŒâïŒïŒºïŒâïŒâã¡ããã·
ã€ããã¢ã»ãã¢ãããâïŒâãïŒïŒâã¡ãã«â1Hâ
ããã©ãŸãŒã«âïŒã€ã«ïŒããªã¡ãã«ãã»ãã¢âïŒ
âãšã³âïŒâã«ã«ãã³é žãïŒâïŒïŒâã¢ããâïŒ
âããšãã«ã¢ã»ãã¢ããïŒâïŒâã¡ããã·âïŒâ
ãªããœâïŒâãã¢âïŒâã¢ã¶ãã·ã¯ãâãªã¯ãâ
ïŒâãšã³âïŒâã«ã«ãã³é žããã³ãã®ãããªãŠã
å¡©çã®å¡©ãªã©ããããããã è¬ç掻æ§ç©è³ªäžãããšãã°ãβâã©ã¯ã¿ã åå
ç©äžïŒäŸãã°ããã·ãªã³é¡ãã»ãã¢ãã¹ããªã³
é¡ïŒã®åŠãæçç©è³ªã¯ãå šè£œå€ïŒïœã«å¯ŸããŠãé
åžž20ã500mgã奜ãŸããã¯60ã250mgã®å²åã§ããŸ
ãã€ã³ã·ãŠãªã³çã¯å šè£œå€ïŒïœã«å¯ŸããŠéåžžïŒã
80åäœã奜ãŸããã¯ïŒã40åäœã®å²åã§ãæ¬çºæ
ã®çŽè žæäžçšçµæç©äžã«æ·»å ãããã æ¬çºæçµæç©ã®ç¬¬ïŒã®æ æ§ã¯ãççŽ æ°ïŒä¹è³12
ã®èèªé žã®ã¢ã«ã«ãªéå±å¡©ãæ²¹æ§åºå€äžã«åæ£ç¶
æ ã§å«æãããå¿ èŠã«å¿ããŠä»ã®æ·»å å€ãé åã
ãéãã»ã«åã®è£œå€ã§ããããã®è£œå€ã«ãã€ãŠ
ã¯ãéåžžåœè©²è£œå€ãšåæã«ããŸãã¯åœè©²è£œå€ãçŽ
è žæäžããåŸè¬ç掻æ§ç©è³ªãçŽè žæäžãããã æ¬çºæã®ç¬¬ïŒã®æ æ§ã¯ãäžç¬¬ïŒæ æ§ã®è£œå€ã«ã
ãã«è¬ç掻æ§ç©è³ªãé åãã補å€ã§ããã æ¬çºæã®çµæç©ã補å€åããã«ããã€ãŠã¯ãé
åžžã®èéåå€ã®åã«ããããççŽ æ°ïŒä¹è³12ã®è
èªé žã®ã¢ã«ã«ãªéå±å¡©ãå¿ èŠã«å¿ããŠè¬ç掻æ§ç©
質ã液ç¶ã®æ²¹æ§åºå€ã«åæ£ãããæžæ¿ç¶ãããã¯
è»èç¶ã®ãã®ãè»ã«ãã»ã«ã«å å¡«ãããããŸãã¯
ããŠãŒãã«å ¥ããŠçšææ³šå ¥ããå€åãšããããšã«
ãã調æŽããããããã補å€ã¯èªäœæ¢ç¥ã®æ¹æ³ã«
ãã€ãŠèª¿æŽãããã æ¬çºæã«ãããŠãåºå€ãšããŠã¯æ²¹æ§åºå€ã䜿çš
ãããæ²¹æ§åºå€ãšããŠã¯æ€ç©æ§æ²¹èé¡ãããšãã°
ã©ãã«ã»ã€æ²¹ããªãªãŒãæ²¹ãããŠã¢ãã³ã·æ²¹ãã
ãã·æ²¹ãã«ã«ãªæ²¹ãèèªé žã®ã°ãªã»ãªã³ãšã¹ã
ã«ãããšãã°ããŠã€ãããŸãŒã«ïŒãã€ããã€ã
ããŒãã«ç€Ÿè£œïŒãSBâåºå€ïŒã«ãã¬ããååŠç€Ÿ
補ïŒãO.D.O.ïŒæ¥æž 補油瀟補ïŒãªã©ããããã
ãã æ¬çºæã®çµæç©ã¯ãäžè¬ã«ãåºå€ã«ççŽ æ°ïŒã
12ã®èèªé žã®ã¢ã«ã«ãªéå±å¡©ãæ·»å ããåäžã«å
æ£ãããåŸãå¿ èŠã«å¿ããŠè¬ç掻æ§ç©è³ªãæ·»å
ããåäžã«åæ£ãããŠè£œé ããããæ·»å ã®é åºã¯
å¿ ãããäžèšã®é åºã«éå®ããããã®ã§ã¯ãªãä»»
æã«éžæã§ãããããã«ãããã«æé žåå€ãé²è
å€ãé ããå€ã賊圢ãªã©ãæ·»å ããŠãããã ççŽ æ°ïŒã12ã®èèªé žã®ã¢ã«ã«ãªéå±å¡©ããã³
è¬ç掻æ§ç©è³ªã®ç²åŸã¯100ã¡ãã·ãŠä»¥äžã奜ãŸã
ãã æ¬çºæã®çµæç©ã«ããã°ãããšãã°è¬ç掻æ§ç©
質ãšããŠÎ²âã©ã¯ã¿ã æçç©è³ªã䜿çšããå Žåã®
æäžéã¯æ人ïŒå125mgãïŒïœå䟡ã§ããããŸã
該èèªé žã®ã¢ã«ã«ãªéå±å¡©ã¯æ人ïŒåïŒmgã200
mgæäžãããããšã«ãªãã ãŸãã該èèªé žã®ã¢ã«ã«ãªéå±å¡©ã¯ãäžè¬çã«
ã¯æ¢ç¥ã§ãããããšãã°è©²èèªé žã«ã¢ã«ã«ãªéå±
ãäœçšãããããšã«ãã€ãŠåŸãããã ãªããççŽ æ°ïŒã12ã®èèªé žã¯ãäžè¬ã«ã¯ãæ¢
ç¥ã§ããã倩ç¶æ²¹èã®å æ°Žå解ãã«ã«ãã³é žã®äž
è¬ç補æ³ãªã©ã®èªäœæ¢ç¥ã®æ¹æ³ã«ãã€ãŠåŸãã
ãã å®æœäŸ ïŒ ãŠã€ãããŸãŒã«ïŒšâ15ïŒãã€ããã€ãããŒãã«
瀟補ïŒ8.25ïœã40â以äžã§æº¶è§£ããã®ã¡ã100ã¡
ãã·ãŠã®ç¯©ãééããã«ããªã«é žãããªãŠã 0.50
ïœãå ããããæ¹æããŠåäžã«åæ£ãããåŸã
100ã¡ãã·ãŠã®ç¯©ãééããã¢ã³ãã·ãªã³ãããª
ãŠã ïŒAMâNaãšç¥ç§°ããïŒ1.25ïœå䟡ãå ããŠ
åäžã«åæ£ãããããããåå€çšã³ã³ããã«ïŒïœ
ããŠå å¡«ããŠæåããèéåå€ãšããã å®æœäŸ ïŒ å®æœäŸïŒã®æ¹æ³ã«æºããŠä»¥äžã®åŠæ¹ã®èéåå€
ãåŸããäžè¡šïŒäžNaã¯ãããªãŠã å¡©ã瀺ãã
詳ããã¯ãæ¬çºæã¯ãè¬ç掻æ§ç©è³ªã®ãçŽè žãã
ã®åžåãæ¹åãããçŽè žæäžçšçµæç©ã«é¢ããã çµå£æäžã«ããè¡äžãžã®åžåã®å°é£ãªè¬ç掻æ§
ç©è³ªã¯ãäžè¬ã«æ³šå°ã«ãã€ãŠæäžããŠããããã
ããªãã泚å°ã®å Žåã¯ãçŒçã䌎ã䜿çšã«éããŠ
䟿å®çã§ãªãããã€çæçž®çãªã©ã®å±éºæ§ãªã©ã
䌎ããå¿ ãããæºè¶³ã®ãããã®ã§ã¯ãªãããŸãæ
çç©è³ªäžã®æ¯èŒçåžåæ§ã®ããè¬ç掻æ§ç©è³ªãçµ
å£æäžããå Žåããè¡äžæ¿åºŠã極ããŠçæéã®ã
ã¡ã«äœæžããããæäžéãå¢ãããããããã¯æ
äžåæ°ãå€ãããªããã°ãªããããã®éçããæª
åžååã«ãã€ãŠè žå åžžåšèã殺èãããã¯éèã
ãããã®çµæè žå èå¢ã®å€è²ãã¿ãèšåºäžå¥œãŸã
ããªãåé¡ãæ¹èµ·ããŠãããããã«ã¯ãçµå£æäž
ã«ãã€ãŠã¯æ¶å管å ã«ãããŠæ¶åé µçŽ ã«ãã€ãŠå
解ãããååç©ãå€ãç¥ãããŠããã ãããå®æ ãããçäœå ã«è¯å¥œã«è¬ç掻æ§ç©è³ª
ãåžåãããããã«ãçš®ã ã®è©Šã¿ããªãããŠã
ããç¹ã«çŽè žå æäžã«ããè©Šã¿ãå€ãã ããããªãããåŸæ¥ç¥ãããŠããçŽè žæäžçšçµ
æç©ã¯ãåžåãäžååã§ãã€ãããå®å šæ§ã®ç¹ã§
æºè¶³ã®ãããã®ã§ãªãã€ããã極ããŠç¹å®ããã
è¬ç掻æ§ç©è³ªã«ã€ããŠããåžåä¿é²å¹æã瀺ããª
ãã€ããããããã¯çŽè žç²èåºæ¿äœçšãæããã
ã§ãå¿ ãããæºè¶³ã®ãããã®ã§ã¯ãªããç¹ã«ãã
ãã·ãªã³é¡ãã»ãã¢ãã¹ããªã³é¡ã®ãããªÎ²âã©
ã¯ã¿ã ååç©ãã€ã³ã·ãŠãªã³ãªã©ã®é«ååããã¿
ã€ãã¯ãããèªäœã§ã¯çŽè žããåžåãããããã
ãã®çŽè žæäžè£œå€ã®éçºã®è©Šã¿ããªãããŠãã
ããããããæºè¶³ã®ãããã®ã§ã¯ãªãã æ¬çºæè ãã¯ããã®ãããªå®æ ã«éã¿ãŠéæç
究ãéããçµæãççŽ æ°ïŒã12ã®èèªé žã®ã¢ã«ã«
ãªéå±å¡©ãããã»ã«ã圢æããŠããªãå Žåã«æ¥µã
ãŠåºæ±ãªè¬ç掻æ§ç©è³ªã«å¯ŸããŠãç¹ã«ãããã·ãª
ã³é¡ãã»ãã¢ãã¹ããªã³é¡ã®åŠãβâã©ã¯ã¿ã å
åç©ãã€ã³ã·ãŠãªã³ãªã©ã®é«ååããã¿ã€ãã«ã€
ããŠããçŽè žããã®è¡äžãžã®åžåä¿é²å¹æã瀺ã
ããšãèŠåºããããã«æ€èšãéããçµæãæ¬çºæ
ãå®æããã«è³ã€ãã å³ã¡ãæ¬çºæã¯ãççŽ æ°ïŒä¹è³12ã®èèªé žã®ã¢
ã«ã«ãªéå±å¡©ãæ²¹æ§åºå€äžã«åæ£ç¶æ ã§å«æãã
ãŠãªãããšãç¹åŸŽãšããéãã»ã«åçŽè žæäžçšçµ
æç©ã§ããã æ¬çºæã§äœ¿çšãããççŽ æ°ïŒã12ã®èèªé žã®ã¢
ã«ã«ãªéå±å¡©ã¯å€©ç¶ç±æ¥ã®ãã®ã§ããåæç±æ¥ã®
ãã®ã§ããããã奜é©ã«ã¯å€©ç¶ç±æ¥ã®ãã®ã䜿çš
ãããã該èèªé žå¡©ãšããŠã¯ãçŽéç¶ãåå²ç¶ã®
äž¡è ãããããã奜ãŸããã¯çŽéç¶ã®ãã®ããã
ãããã ãããèèªé žã®ã¢ã«ã«ãªéå±å¡©ãšããŠã¯ãããš
ãã°ãã«ããªã³é žå¡©ãã©ãŠãªã³é žå¡©ãªã©ãããã«
奜é©ã«ã¯ãã«ããªã³é žå¡©ããããããã æ¬çºæã§ããççŽ æ°ïŒã12ã®èèªé žã®ã¢ã«ã«ãª
éå±å¡©ãšããŠã¯ãããšãã°ãããªãŠã å¡©ãã«ãªãŠ
ã å¡©ãªã©ããããããã 該èèªé žã®ã¢ã«ã«ãªéå±å¡©ãšããŠã¯ãå ·äœçã«
ã¯ãããšãã°ã«ããªã«é žã®ãããªãŠã å¡©ããã³ã«
ãªãŠã å¡©ïŒãã©ã«ãŽã³é žã®ãããªãŠã å¡©ïŒã«ããª
ã³é žã®ãããªãŠã å¡©ããã³ã«ãªãŠã å¡©ïŒã©ãŠãªã³
é žã®ãããªãŠã å¡©ããã³ã«ãªãŠã å¡©ãªã©ãããã
ããããããã®ã®ãã¡ãäžè¿°ã®ã«ããªã³é žã®å¡©ã
ã©ãŠãªã³é žã®å¡©ã奜é©ã§ããã ããã«å¥œãŸããã¯ãã«ããªã³é žã®å¡©ããããã
ãã ãããççŽ æ°ïŒã12ã®èèªé žã®ã¢ã«ã«ãªéå±å¡©
ã¯åç¬ã§äœ¿çšããŠããããããŸãã¯äºçš®ä»¥äžãçµ
åãããŠäœ¿çšããŠãããã ãã®ççŽ æ°ïŒã12ã®èèªé žã®ã¢ã«ã«ãªéå±å¡©ã®
䜿çšéã¯ãéåžžãå šè£œå€äž0.5ã20ïŒ ã奜ãŸãã
ã¯ïŒã15ïŒ ãããã«å¥œãŸããã¯ïŒã10ïŒ ã§ããã æ¬çºæã§ããè¬ç掻æ§ç©è³ªã¯ãè¡äžã«åžåãã
ãŠè¬å¹ãçºæ®ãããã®ã§ããã°ããããã§ãã
ããç¹ã«ãçµå£æäžãçŽè žæäžã«ãã€ãŠåžåãã
ããåŸæ¥æ³šå°ã«ãã€ãŠã®ã¿æäžãããŠãããã®ã§
ããæ¬çºæã®çµæç©ã䜿çšããããšã«ãã€ãŠãçŽ
è žãã容æã«åžåãããããšã«ãªãã®ã§ããã®ã
ããªé£åžåæ§ã®è¬ç掻æ§ç©è³ªã«å¯ŸããŠãæ¬çºæã®
çŽè žæäžçšçµæç©ã䜿çšããããšã®æ矩ãããã
è¬ç掻æ§ç©è³ªãšããŠã¯ãå ·äœçã«ã¯ãããšãã°Î²
âã©ã¯ã¿ã ç°ãæããååç©ïŒããšãã°ãããã·
ãªã³é¡ãã»ãã¢ãã¹ããªã³é¡ãªã©ïŒãããã¿ã€ã
ç³»ååç©ãªã©ãããããããããã·ãªã³é¡ãšããŠ
ã¯ãããšãã°ã¢ã³ãã·ãªã³ãã·ã¯ã©ã·ãªã³ãã¯ã
ããµã·ãªã³ããã³ãžã«ããã·ãªã³ãã«ã«ããã·ãª
ã³ãããã©ã·ãªã³ãã¡ãŸãã·ãªã³ããã«ããã·ãª
ã³ããã«ã«ã·ãªã³ãïŒ2Sã»5Rã»6RïŒâïŒâãïŒïŒ²ïŒ
âïŒâïŒïŒâãã€ãããªãã·âïŒã»ïŒâããããª
ãžã³âïŒâã«ã«ãããµã¢ããïŒâïŒâããšãã«ã¢
ã»ãã¢ãããâïŒã»ïŒâãžã¡ãã«âïŒâãªããœâ
ïŒâãã¢âïŒâã¢ã¶ãã·ã¯ããïŒã»ïŒã»ïŒããã
ã¿ã³âïŒâã«ã«ãã³é žããã³ãã®ãããªãŠã å¡©ç
ã®å¡©ãªã©ããããããã ã»ãã¢ãã¹ããªã³é¡ãšããŠã¯ããšãã°ã»ãã¢ã
ãã³ãã»ããã·ãã³ãã»ãã¢ãŸãªã³ãã»ãã¢ããª
ãžã³ãã»ãã¢ã»ããªã«ãã»ãã¢ãã¢ã ãã»ããªã©
ãããã»ãã¢ãã³ãã»ãã¢ã¯ããŒã«ãã»ãã¢ãã
ãã·ã«ãã»ãã¢ããªãžã³ãã»ãã©ãžã³ãã»ãã¢ã
ã°ãªã·ã³ãïŒâãïŒâïŒâαâïŒïŒâãšãã«â
ïŒã»ïŒâãžãªããœâïŒâããã©ãžã³âã«ã«ãããµ
ããïŒâαâïŒïŒâããããã·ããšãã«ïŒã¢ã»ã¿ã
ããâïŒâãïŒïŒâã¡ãã«â1Hâããã©ãŸãŒã«âïŒ
âã€ã«ïŒããªã¡ãã«ãâïŒâã»ãã¢ã âïŒâã«ã«
ãã³é žïŒä»¥äžãâ1551ãšç¥ç§°ããïŒãïŒ6Rã»
7RïŒâãïŒïŒºïŒâïŒâã¡ããã·ã€ããâïŒâïŒïŒâã€
ããâïŒâãã¢ãŸãªã³âïŒâã€ã«ïŒâã¢ã»ã¿ã
ããâïŒâãªããœâïŒâãã¢âïŒâã¢ã¶ãã·ã¯ã
ãïŒã»ïŒã»ïŒããªã¯ãâïŒâãšã³âïŒâã«ã«ãã³
é žãïŒ6Rã»7RïŒâïŒâãïŒâã«ã«ããã·âïŒâïŒïŒ
âããããã·ããšãã«ïŒã¢ã»ã¿ãããâïŒâã¡ã
ãã·âïŒâãïŒïŒâã¡ãã«â1Hâããã©ãŸãŒã«â
ïŒâã€ã«âããªïŒã¡ãã«ãâïŒâãªããœâïŒâãª
ããµâïŒâã¢ã¶ãã·ã¯ããïŒã»ïŒã»ïŒããªã¯ã¿â
ïŒâãšã³ïŒâã«ã«ãã³é žãïŒÎ²âãïŒâïŒïŒâã¢ã
ããã¢ãŸãŒã«âïŒâã€ã«ïŒâïŒïŒºïŒâïŒâã¡ããã·
ã€ããã¢ã»ãã¢ãããâïŒâãïŒïŒâã¡ãã«â1Hâ
ããã©ãŸãŒã«âïŒã€ã«ïŒããªã¡ãã«ãã»ãã¢âïŒ
âãšã³âïŒâã«ã«ãã³é žãïŒâïŒïŒâã¢ããâïŒ
âããšãã«ã¢ã»ãã¢ããïŒâïŒâã¡ããã·âïŒâ
ãªããœâïŒâãã¢âïŒâã¢ã¶ãã·ã¯ãâãªã¯ãâ
ïŒâãšã³âïŒâã«ã«ãã³é žããã³ãã®ãããªãŠã
å¡©çã®å¡©ãªã©ããããããã è¬ç掻æ§ç©è³ªäžãããšãã°ãβâã©ã¯ã¿ã åå
ç©äžïŒäŸãã°ããã·ãªã³é¡ãã»ãã¢ãã¹ããªã³
é¡ïŒã®åŠãæçç©è³ªã¯ãå šè£œå€ïŒïœã«å¯ŸããŠãé
åžž20ã500mgã奜ãŸããã¯60ã250mgã®å²åã§ããŸ
ãã€ã³ã·ãŠãªã³çã¯å šè£œå€ïŒïœã«å¯ŸããŠéåžžïŒã
80åäœã奜ãŸããã¯ïŒã40åäœã®å²åã§ãæ¬çºæ
ã®çŽè žæäžçšçµæç©äžã«æ·»å ãããã æ¬çºæçµæç©ã®ç¬¬ïŒã®æ æ§ã¯ãççŽ æ°ïŒä¹è³12
ã®èèªé žã®ã¢ã«ã«ãªéå±å¡©ãæ²¹æ§åºå€äžã«åæ£ç¶
æ ã§å«æãããå¿ èŠã«å¿ããŠä»ã®æ·»å å€ãé åã
ãéãã»ã«åã®è£œå€ã§ããããã®è£œå€ã«ãã€ãŠ
ã¯ãéåžžåœè©²è£œå€ãšåæã«ããŸãã¯åœè©²è£œå€ãçŽ
è žæäžããåŸè¬ç掻æ§ç©è³ªãçŽè žæäžãããã æ¬çºæã®ç¬¬ïŒã®æ æ§ã¯ãäžç¬¬ïŒæ æ§ã®è£œå€ã«ã
ãã«è¬ç掻æ§ç©è³ªãé åãã補å€ã§ããã æ¬çºæã®çµæç©ã補å€åããã«ããã€ãŠã¯ãé
åžžã®èéåå€ã®åã«ããããççŽ æ°ïŒä¹è³12ã®è
èªé žã®ã¢ã«ã«ãªéå±å¡©ãå¿ èŠã«å¿ããŠè¬ç掻æ§ç©
質ã液ç¶ã®æ²¹æ§åºå€ã«åæ£ãããæžæ¿ç¶ãããã¯
è»èç¶ã®ãã®ãè»ã«ãã»ã«ã«å å¡«ãããããŸãã¯
ããŠãŒãã«å ¥ããŠçšææ³šå ¥ããå€åãšããããšã«
ãã調æŽããããããã補å€ã¯èªäœæ¢ç¥ã®æ¹æ³ã«
ãã€ãŠèª¿æŽãããã æ¬çºæã«ãããŠãåºå€ãšããŠã¯æ²¹æ§åºå€ã䜿çš
ãããæ²¹æ§åºå€ãšããŠã¯æ€ç©æ§æ²¹èé¡ãããšãã°
ã©ãã«ã»ã€æ²¹ããªãªãŒãæ²¹ãããŠã¢ãã³ã·æ²¹ãã
ãã·æ²¹ãã«ã«ãªæ²¹ãèèªé žã®ã°ãªã»ãªã³ãšã¹ã
ã«ãããšãã°ããŠã€ãããŸãŒã«ïŒãã€ããã€ã
ããŒãã«ç€Ÿè£œïŒãSBâåºå€ïŒã«ãã¬ããååŠç€Ÿ
補ïŒãO.D.O.ïŒæ¥æž 補油瀟補ïŒãªã©ããããã
ãã æ¬çºæã®çµæç©ã¯ãäžè¬ã«ãåºå€ã«ççŽ æ°ïŒã
12ã®èèªé žã®ã¢ã«ã«ãªéå±å¡©ãæ·»å ããåäžã«å
æ£ãããåŸãå¿ èŠã«å¿ããŠè¬ç掻æ§ç©è³ªãæ·»å
ããåäžã«åæ£ãããŠè£œé ããããæ·»å ã®é åºã¯
å¿ ãããäžèšã®é åºã«éå®ããããã®ã§ã¯ãªãä»»
æã«éžæã§ãããããã«ãããã«æé žåå€ãé²è
å€ãé ããå€ã賊圢ãªã©ãæ·»å ããŠãããã ççŽ æ°ïŒã12ã®èèªé žã®ã¢ã«ã«ãªéå±å¡©ããã³
è¬ç掻æ§ç©è³ªã®ç²åŸã¯100ã¡ãã·ãŠä»¥äžã奜ãŸã
ãã æ¬çºæã®çµæç©ã«ããã°ãããšãã°è¬ç掻æ§ç©
質ãšããŠÎ²âã©ã¯ã¿ã æçç©è³ªã䜿çšããå Žåã®
æäžéã¯æ人ïŒå125mgãïŒïœå䟡ã§ããããŸã
該èèªé žã®ã¢ã«ã«ãªéå±å¡©ã¯æ人ïŒåïŒmgã200
mgæäžãããããšã«ãªãã ãŸãã該èèªé žã®ã¢ã«ã«ãªéå±å¡©ã¯ãäžè¬çã«
ã¯æ¢ç¥ã§ãããããšãã°è©²èèªé žã«ã¢ã«ã«ãªéå±
ãäœçšãããããšã«ãã€ãŠåŸãããã ãªããççŽ æ°ïŒã12ã®èèªé žã¯ãäžè¬ã«ã¯ãæ¢
ç¥ã§ããã倩ç¶æ²¹èã®å æ°Žå解ãã«ã«ãã³é žã®äž
è¬ç補æ³ãªã©ã®èªäœæ¢ç¥ã®æ¹æ³ã«ãã€ãŠåŸãã
ãã å®æœäŸ ïŒ ãŠã€ãããŸãŒã«ïŒšâ15ïŒãã€ããã€ãããŒãã«
瀟補ïŒ8.25ïœã40â以äžã§æº¶è§£ããã®ã¡ã100ã¡
ãã·ãŠã®ç¯©ãééããã«ããªã«é žãããªãŠã 0.50
ïœãå ããããæ¹æããŠåäžã«åæ£ãããåŸã
100ã¡ãã·ãŠã®ç¯©ãééããã¢ã³ãã·ãªã³ãããª
ãŠã ïŒAMâNaãšç¥ç§°ããïŒ1.25ïœå䟡ãå ããŠ
åäžã«åæ£ãããããããåå€çšã³ã³ããã«ïŒïœ
ããŠå å¡«ããŠæåããèéåå€ãšããã å®æœäŸ ïŒ å®æœäŸïŒã®æ¹æ³ã«æºããŠä»¥äžã®åŠæ¹ã®èéåå€
ãåŸããäžè¡šïŒäžNaã¯ãããªãŠã å¡©ã瀺ãã
ãè¡šã
ïŒ ããã¢ã ããšã€ã³ããªã°ãªã»ã©ã€ã
ããããŠå®æœäŸïŒãïŒã§åŸãããèéåå€ã«ã€
ããŠã®è¡äžãžã®åžåæ§ãè¡æŒ¿æ¿åºŠã«ãã€ãŠã枬å®
ããããã®çµæãè¡šïŒã«ç€ºãã 枬å®æ¹æ³ïŒ24æé絶é£ããã€ãã®èéããçŽïŒ
cmã®æ·±éšã«çµæç©ãæäžããã è¡æŒ¿æ¿åºŠã®æž¬å®ã¯ãçµæçã«é éèããæ¡è¡
ããåžžæ³ã«ãã€ãŠåŸãè¡æŒ¿ãçç©åŠçæ€å®æ³ã«ã
ã€ãŠæŽ»æ§æ¿åºŠãå®éããã ããªãã¡ãæ¥æ¬æçç©è³ªåºæºã«æºæ ããæ€å®è
ãšããŠã¯ããã·ãªã³ç³»æçç©è³ªã®å Žåã«ã¯ãµã«ã·
ã ã«ãã¢ïŒS.luteaïŒãããŸããã»ãã¢ãã¹ã
ãªã³ç³»æçç©è³ªã®å Žåã«ã¯ããã«ã¹ ãºãããªã¹
ïŒB.subtilisïŒãçšããããŒããŒãã€ã¹ã¯æ³ã§37
âã15ã20æéå¹é€æ€å®ããã
ããããŠå®æœäŸïŒãïŒã§åŸãããèéåå€ã«ã€
ããŠã®è¡äžãžã®åžåæ§ãè¡æŒ¿æ¿åºŠã«ãã€ãŠã枬å®
ããããã®çµæãè¡šïŒã«ç€ºãã 枬å®æ¹æ³ïŒ24æé絶é£ããã€ãã®èéããçŽïŒ
cmã®æ·±éšã«çµæç©ãæäžããã è¡æŒ¿æ¿åºŠã®æž¬å®ã¯ãçµæçã«é éèããæ¡è¡
ããåžžæ³ã«ãã€ãŠåŸãè¡æŒ¿ãçç©åŠçæ€å®æ³ã«ã
ã€ãŠæŽ»æ§æ¿åºŠãå®éããã ããªãã¡ãæ¥æ¬æçç©è³ªåºæºã«æºæ ããæ€å®è
ãšããŠã¯ããã·ãªã³ç³»æçç©è³ªã®å Žåã«ã¯ãµã«ã·
ã ã«ãã¢ïŒS.luteaïŒãããŸããã»ãã¢ãã¹ã
ãªã³ç³»æçç©è³ªã®å Žåã«ã¯ããã«ã¹ ãºãããªã¹
ïŒB.subtilisïŒãçšããããŒããŒãã€ã¹ã¯æ³ã§37
âã15ã20æéå¹é€æ€å®ããã
ãè¡šã
ãè¡šã
å®æœäŸ ïŒ
å®æœäŸïŒã®æ¹æ³ã«æºããŠè¡šïŒã®è©Šææ¬ã«èšèŒã
ãåŠæ¹ã®èéåå€ãåŸãã ããããŠåŸãããåå€ãå¥åžžæ人ç·åã«æäžã
ããšãã®åè¬ç掻æ§ç©è³ªã®å°¿äžææ³éã枬å®ã
ãããã®çµæãè¡šïŒã«ç€ºãã å°¿äžææ³éã®æž¬å®ã¯ãæäžåŸçµæçã«æ¡å°¿ãã
é©å®åžéããŠãå®æœäŸïŒã®æ¹æ³ã«åŸã€ãŠå®éã
ãã ãªããè¡šïŒã®å°¿äžææ³éã¯ãæäžéã«å¯Ÿããã
ãŒã»ã³ãã§ããã
ãåŠæ¹ã®èéåå€ãåŸãã ããããŠåŸãããåå€ãå¥åžžæ人ç·åã«æäžã
ããšãã®åè¬ç掻æ§ç©è³ªã®å°¿äžææ³éã枬å®ã
ãããã®çµæãè¡šïŒã«ç€ºãã å°¿äžææ³éã®æž¬å®ã¯ãæäžåŸçµæçã«æ¡å°¿ãã
é©å®åžéããŠãå®æœäŸïŒã®æ¹æ³ã«åŸã€ãŠå®éã
ãã ãªããè¡šïŒã®å°¿äžææ³éã¯ãæäžéã«å¯Ÿããã
ãŒã»ã³ãã§ããã
ãè¡šã
ãè¡šã
ãè¡šã
å®æœäŸ ïŒ
å®æœäŸïŒã®æ¹æ³ã«æºããŠè¡šïŒã®è©Šææ¬ã«èšèŒã
ãåŠæ¹ã®èéåå€ãåŸãã ããããŠåŸãããèéåå€ãæäžãããšãã®è¡
ç³å€ã®çµæçå€åããèèªé žç¡æ·»å ã®èéåå€ã
å¯Ÿç §ãšããŠæž¬å®ãããã®æ瞟ãè¡šïŒã«ç€ºããã 枬å®æ³ïŒ24æé絶é£ããã家å ã«åå€ãèéã
ãïŒcmã®æ·±éšã«æäžãããè¡ç³å€ã¯ãçµæçã«è³
éèããæ¡åããã°ã«ã³ãŒã¹ãªãã·ããŒãŒæ³ã«ã
ã€ãŠæž¬å®ããã
ãåŠæ¹ã®èéåå€ãåŸãã ããããŠåŸãããèéåå€ãæäžãããšãã®è¡
ç³å€ã®çµæçå€åããèèªé žç¡æ·»å ã®èéåå€ã
å¯Ÿç §ãšããŠæž¬å®ãããã®æ瞟ãè¡šïŒã«ç€ºããã 枬å®æ³ïŒ24æé絶é£ããã家å ã«åå€ãèéã
ãïŒcmã®æ·±éšã«æäžãããè¡ç³å€ã¯ãçµæçã«è³
éèããæ¡åããã°ã«ã³ãŒã¹ãªãã·ããŒãŒæ³ã«ã
ã€ãŠæž¬å®ããã
ãè¡šã
å®æœäŸ ïŒ
æäžçµæç©ã®èª¿è£œ
ïŒè©ŠæïŒïŒ
ã»ãã¢ãŸãªã³100mgå䟡ãšã¿ãŠãã³ãŒã«é
žãã
ãªãŠã 540mgãå«ã氎溶液100mläžã«ïŒâã¢ããªã¬
ã€ã³ã®çèç©ïŒããªã¢ã«ãå ããUltrasonic
generator US150ïŒæ¥æ¬ç²Ÿæ©è£œäœæïŒãçšãïŒå
éè¶ é³æ³¢æ¹æããéæãªãã»ã«æº¶æ¶²ã調補ããã ïŒè©ŠæïŒïŒ ã»ãã¢ãŸãªã³100mgå䟡ãšã¿ãŠãã³ãŒã«é žãã
ãªãŠã 540mgãå«ã氎溶液100mläžã«ãªã¬ã€ã³é žïŒ
ããªã¢ã«ãå ããUltrasonic generator US150
ïŒæ¥æ¬ç²Ÿæ©è£œäœæïŒãçšãïŒåéè¶ é³æ³¢æ¹æãã
éæãªãã»ã«æº¶æ¶²ã調補ããã ïŒè©ŠæïŒïŒ ã»ãã¢ãŸãªã³100mgå䟡ãšã¿ãŠãã³ãŒã«é žãã
ãªãŠã 540mgãå«ã氎溶液100mläžã«ãªã¬ã€ã³é žã
ããªãŠã ïŒããªã¢ã«ãå ããUltrasonic
generator US150ïŒæ¥æ¬ç²Ÿæ©è£œäœæïŒãçšãïŒå
éè¶ é³æ³¢æ¹æããéæãªãã»ã«æº¶æ¶²ã調補ããã ïŒè©ŠæïŒïŒ ã»ãã¢ãŸãªã³100mgå䟡ãšã¿ãŠãã³ãŒã«é žãã
ãªãŠã 540mgãå«ã氎溶液100mläžã«ã«ããªã³é žã
ããªãŠã ïŒããªã¢ã«ãå ããïŒåéè¶ é³æ³¢æ¹æ
ããéæãªãã»ã«æº¶æ¶²ã調補ããã ïŒè©ŠæïŒïŒ ã»ãã¢ãŸãªã³100mgå䟡ãšã¿ãŠã³ããŒã«é žãã
ãªãŠã 540mgãæ°Ž100mläžã«å ããïŒåéè¶ é³æ³¢æ¹
æããéæãªãã»ã«æº¶æ¶²ã調補ããã ïŒè©ŠæïŒïŒ ã»ãã¢ãŸãªã³100mgå䟡ãšïŒâã¢ããªã¬ã€ã³ã®
çèç©ïŒããªã¢ã«ãçèããåå€åºå€Witepsol
â15 37ïœã«å ãæ¹æããåäžã«åæ£ãããã ïŒè©ŠæïŒïŒ ã»ãã¢ãŸãªã³100mgå䟡ãšãªã¬ã€ã³é žïŒããªã¢
ã«ãçèããåå€åºå€Witepsol â15 37ïœã«
å ãæ¹æããåäžã«åæ£ãããã ïŒè©ŠæïŒïŒ ã»ãã¢ãŸãªã³100mgå䟡ãšã«ããªã³é žãããªãŠ
ã ïŒããªã¢ã«ãçèããåå€åºå€Witepsol â
1537ïœã«å ãæ¹æããåäžã«åæ£ãããã ïŒè©ŠæïŒïŒ ã»ãã¢ãŸãªã³100mgå䟡ãšãªã¬ã€ã³é žãããªãŠ
ã ïŒããªã¢ã«ãçèããåå€åºå€Witepsol â
15 37ïœã«å ãæ¹æããåäžã«åæ£ãããã ïŒè©Šæ10ïŒ ã»ãã¢ãŸãªã³100mgå䟡ã泚å°çšççé£å¡©æ°Žã«
溶解ãã50mlãšããã ïŒè©Šæ11ïŒ ã»ãã¢ãŸãªã³100mgå䟡ãæ°Ž100mlã«å ã溶解ã
ãã å®éšæ¹æ³ å®éšåç©ãšããŠWisterç³»éæ§ã©ãããäœé180
ã210ïœãäžå€çµ¶é£ãã䜿çšãããçèå æäžã
é€ãåè©Šæãšãã»ãã¢ãŸãªã³ãšããŠã®æäžéã10
mgå䟡ïŒKgãšãªãããã泚å°çãçšããŠèéãã
æäžãããçèå æäžã®å Žåã¯åããã»ãã¢ãŸãª
ã³ãšããŠã®æäžéã100mgå䟡ïŒKgãšãªãããã
å€§è ¿éšçèå ã«æ³šå°ããã åè©ŠæãæäžåŸãé éèããçµæçã«æ¡è¡ãè¡
ããè¡æž ãåé¢ããè¡æž äžã®ã»ãã¢ãŸãªã³æ¿åºŠã
æ€å®èãšããŠBacillus subtilis ATCC 6633ãçš
ããçç©åŠçéæ³ã«ãã€ãŠæž¬å®ããã åŸãããè¡æž äžæ¿åºŠããè¡äžæ¿åºŠäžé¢ç©
ïŒAUCïŒãèšç®ããçèå æäžæã®AUCã«å¯Ÿãã
åè©Šææäžæã®AUCã®æ¯ãåããBioavailability
ãæ±ããããã®çµæã¯ãè¡šïŒã®ãšããã§ããã
ãªãŠã 540mgãå«ã氎溶液100mläžã«ïŒâã¢ããªã¬
ã€ã³ã®çèç©ïŒããªã¢ã«ãå ããUltrasonic
generator US150ïŒæ¥æ¬ç²Ÿæ©è£œäœæïŒãçšãïŒå
éè¶ é³æ³¢æ¹æããéæãªãã»ã«æº¶æ¶²ã調補ããã ïŒè©ŠæïŒïŒ ã»ãã¢ãŸãªã³100mgå䟡ãšã¿ãŠãã³ãŒã«é žãã
ãªãŠã 540mgãå«ã氎溶液100mläžã«ãªã¬ã€ã³é žïŒ
ããªã¢ã«ãå ããUltrasonic generator US150
ïŒæ¥æ¬ç²Ÿæ©è£œäœæïŒãçšãïŒåéè¶ é³æ³¢æ¹æãã
éæãªãã»ã«æº¶æ¶²ã調補ããã ïŒè©ŠæïŒïŒ ã»ãã¢ãŸãªã³100mgå䟡ãšã¿ãŠãã³ãŒã«é žãã
ãªãŠã 540mgãå«ã氎溶液100mläžã«ãªã¬ã€ã³é žã
ããªãŠã ïŒããªã¢ã«ãå ããUltrasonic
generator US150ïŒæ¥æ¬ç²Ÿæ©è£œäœæïŒãçšãïŒå
éè¶ é³æ³¢æ¹æããéæãªãã»ã«æº¶æ¶²ã調補ããã ïŒè©ŠæïŒïŒ ã»ãã¢ãŸãªã³100mgå䟡ãšã¿ãŠãã³ãŒã«é žãã
ãªãŠã 540mgãå«ã氎溶液100mläžã«ã«ããªã³é žã
ããªãŠã ïŒããªã¢ã«ãå ããïŒåéè¶ é³æ³¢æ¹æ
ããéæãªãã»ã«æº¶æ¶²ã調補ããã ïŒè©ŠæïŒïŒ ã»ãã¢ãŸãªã³100mgå䟡ãšã¿ãŠã³ããŒã«é žãã
ãªãŠã 540mgãæ°Ž100mläžã«å ããïŒåéè¶ é³æ³¢æ¹
æããéæãªãã»ã«æº¶æ¶²ã調補ããã ïŒè©ŠæïŒïŒ ã»ãã¢ãŸãªã³100mgå䟡ãšïŒâã¢ããªã¬ã€ã³ã®
çèç©ïŒããªã¢ã«ãçèããåå€åºå€Witepsol
â15 37ïœã«å ãæ¹æããåäžã«åæ£ãããã ïŒè©ŠæïŒïŒ ã»ãã¢ãŸãªã³100mgå䟡ãšãªã¬ã€ã³é žïŒããªã¢
ã«ãçèããåå€åºå€Witepsol â15 37ïœã«
å ãæ¹æããåäžã«åæ£ãããã ïŒè©ŠæïŒïŒ ã»ãã¢ãŸãªã³100mgå䟡ãšã«ããªã³é žãããªãŠ
ã ïŒããªã¢ã«ãçèããåå€åºå€Witepsol â
1537ïœã«å ãæ¹æããåäžã«åæ£ãããã ïŒè©ŠæïŒïŒ ã»ãã¢ãŸãªã³100mgå䟡ãšãªã¬ã€ã³é žãããªãŠ
ã ïŒããªã¢ã«ãçèããåå€åºå€Witepsol â
15 37ïœã«å ãæ¹æããåäžã«åæ£ãããã ïŒè©Šæ10ïŒ ã»ãã¢ãŸãªã³100mgå䟡ã泚å°çšççé£å¡©æ°Žã«
溶解ãã50mlãšããã ïŒè©Šæ11ïŒ ã»ãã¢ãŸãªã³100mgå䟡ãæ°Ž100mlã«å ã溶解ã
ãã å®éšæ¹æ³ å®éšåç©ãšããŠWisterç³»éæ§ã©ãããäœé180
ã210ïœãäžå€çµ¶é£ãã䜿çšãããçèå æäžã
é€ãåè©Šæãšãã»ãã¢ãŸãªã³ãšããŠã®æäžéã10
mgå䟡ïŒKgãšãªãããã泚å°çãçšããŠèéãã
æäžãããçèå æäžã®å Žåã¯åããã»ãã¢ãŸãª
ã³ãšããŠã®æäžéã100mgå䟡ïŒKgãšãªãããã
å€§è ¿éšçèå ã«æ³šå°ããã åè©ŠæãæäžåŸãé éèããçµæçã«æ¡è¡ãè¡
ããè¡æž ãåé¢ããè¡æž äžã®ã»ãã¢ãŸãªã³æ¿åºŠã
æ€å®èãšããŠBacillus subtilis ATCC 6633ãçš
ããçç©åŠçéæ³ã«ãã€ãŠæž¬å®ããã åŸãããè¡æž äžæ¿åºŠããè¡äžæ¿åºŠäžé¢ç©
ïŒAUCïŒãèšç®ããçèå æäžæã®AUCã«å¯Ÿãã
åè©Šææäžæã®AUCã®æ¯ãåããBioavailability
ãæ±ããããã®çµæã¯ãè¡šïŒã®ãšããã§ããã
ãè¡šã
ãè¡šã
å®æœäŸ ïŒ
åå€ã®èª¿è£œ
åå€ã®èª¿è£œã¯ãŠã€ãããŸãŒã«ãçŽ40ã50âã®ãª
ãã¹ãäœæž©ã§çèããããã«äºã100ã¡ãã·ãŠã®
篩ã§ç¯©éããäž»è¬ããã³èèªé žãããªãŠã å¡©ãæ·»
å ããŠæžæ¿ãããããããã©ã¹ããã¯æ§ã®ã³ã³ã
ããŒã«æ³šå ¥ããŠå·åŽããæåãè¡ãçèæ³ã«ãã€
ããå®éšã«äœ¿çšããåå€ïŒåã®åŠæ¹ã¯ïŒåå€ïŒå
ã®åŠæ¹ïŒã®é ã«ç€ºããšããã§ããããªããå¯Ÿç §ãš
ããŠèèªé žãããªãŠã ç¡æ·»å ã®ãã®ã䜿çšããã 枬å®æ¹æ³ äœéçŽ2.5Kgã®çœè²éæ§å®¶å ïŒå¹ãäžçŸ€ãšãã
å®éšå24æé絶é£ãããã®ã¡ãåå€ïŒåãæäž
ããåå€ã®æŒåºãé²ãããã«ã¯ãªããã§èéãæ
ããåå€æäžåŸãåæ¡è¡æéæ¯ã«çŽïŒmlã®è¡æ¶²ã
è³éèããæ¡è¡ããã è¡æ¶²äžã®æªå€åäœæ¿åºŠã®æž¬å®ã¯ãé«é液äœã¯ã
ããã°ã©ãæ³ã§è¡ã€ãããã®çµæãè¡šïŒããã³ç¬¬
ïŒå³ã«ã°ã©ãã§ç€ºãã ãã®çµæããã³å®æœäŸïŒã®çµæãããæ¬é¡çºæ
ã氎溶æ§è¬ç掻æ§ç©è³ªã油溶æ§è¬ç掻æ§ç©è³ªãªã
ã³ã«æ°Žããã³æ²¹äžæº¶æ§è¬ç掻æ§ç©è³ªïŒã€ã³ã·ãŠãª
ã³çïŒããããã¿ã€ãã®è¬ç掻æ§ç©è³ªã«å¯ŸããŠå¹
æããããšãæããã§ããããŸãããããããã
ãã¿ã€ãã®è¬ç掻æ§ç©è³ªã«å¯ŸããŠãåçš®èèªé žå¡©
ã®äžã§ããæ¬é¡çºæã§äœ¿çšãããççŽ æ°ïŒã12ã®
ãã®ãç¹ã«æå¹ã§ããããšãæããã§ããã ïŒåå€ïŒåã®åŠæ¹ïŒ âã¢ã»ãã¢ããããšã³åå€ ã¢ã»ãã¢ããããšã³ 100mg èèªé žãããªãŠã å¡© 36mg ãŠã€ãããŸãŒã« 1064mg 1200mg âã€ã³ãã¡ã¿ã·ã³åå€ ã€ã³ãã¡ã¿ã·ã³ 25mg èèªé žãããªãŠã å¡© 30mg ãŠã€ãããŸãŒã« 945mg 1000mg âã¢ããããªã³åå€ ã¢ããããªã³ 50mg èèªé žãããªãŠã å¡© 36mg ãŠã€ãããŸãŒã« 1114mg 1200mg âãžã¯ãããšããã¯ãããªãŠã åå€ ãžã¯ãããšããã¯ãããªãŠã 50mg èèªé žãããªãŠã å¡© 60mg ãŠã€ãããŸãŒã« 1890mg 2000mg âã¹ã«ããªã³åå€ ã¹ã«ããªã³ 100mg èèªé žãããªãŠã å¡© 36mg ãŠã€ãããŸãŒã« 1064mg 1200mg
ãã¹ãäœæž©ã§çèããããã«äºã100ã¡ãã·ãŠã®
篩ã§ç¯©éããäž»è¬ããã³èèªé žãããªãŠã å¡©ãæ·»
å ããŠæžæ¿ãããããããã©ã¹ããã¯æ§ã®ã³ã³ã
ããŒã«æ³šå ¥ããŠå·åŽããæåãè¡ãçèæ³ã«ãã€
ããå®éšã«äœ¿çšããåå€ïŒåã®åŠæ¹ã¯ïŒåå€ïŒå
ã®åŠæ¹ïŒã®é ã«ç€ºããšããã§ããããªããå¯Ÿç §ãš
ããŠèèªé žãããªãŠã ç¡æ·»å ã®ãã®ã䜿çšããã 枬å®æ¹æ³ äœéçŽ2.5Kgã®çœè²éæ§å®¶å ïŒå¹ãäžçŸ€ãšãã
å®éšå24æé絶é£ãããã®ã¡ãåå€ïŒåãæäž
ããåå€ã®æŒåºãé²ãããã«ã¯ãªããã§èéãæ
ããåå€æäžåŸãåæ¡è¡æéæ¯ã«çŽïŒmlã®è¡æ¶²ã
è³éèããæ¡è¡ããã è¡æ¶²äžã®æªå€åäœæ¿åºŠã®æž¬å®ã¯ãé«é液äœã¯ã
ããã°ã©ãæ³ã§è¡ã€ãããã®çµæãè¡šïŒããã³ç¬¬
ïŒå³ã«ã°ã©ãã§ç€ºãã ãã®çµæããã³å®æœäŸïŒã®çµæãããæ¬é¡çºæ
ã氎溶æ§è¬ç掻æ§ç©è³ªã油溶æ§è¬ç掻æ§ç©è³ªãªã
ã³ã«æ°Žããã³æ²¹äžæº¶æ§è¬ç掻æ§ç©è³ªïŒã€ã³ã·ãŠãª
ã³çïŒããããã¿ã€ãã®è¬ç掻æ§ç©è³ªã«å¯ŸããŠå¹
æããããšãæããã§ããããŸãããããããã
ãã¿ã€ãã®è¬ç掻æ§ç©è³ªã«å¯ŸããŠãåçš®èèªé žå¡©
ã®äžã§ããæ¬é¡çºæã§äœ¿çšãããççŽ æ°ïŒã12ã®
ãã®ãç¹ã«æå¹ã§ããããšãæããã§ããã ïŒåå€ïŒåã®åŠæ¹ïŒ âã¢ã»ãã¢ããããšã³åå€ ã¢ã»ãã¢ããããšã³ 100mg èèªé žãããªãŠã å¡© 36mg ãŠã€ãããŸãŒã« 1064mg 1200mg âã€ã³ãã¡ã¿ã·ã³åå€ ã€ã³ãã¡ã¿ã·ã³ 25mg èèªé žãããªãŠã å¡© 30mg ãŠã€ãããŸãŒã« 945mg 1000mg âã¢ããããªã³åå€ ã¢ããããªã³ 50mg èèªé žãããªãŠã å¡© 36mg ãŠã€ãããŸãŒã« 1114mg 1200mg âãžã¯ãããšããã¯ãããªãŠã åå€ ãžã¯ãããšããã¯ãããªãŠã 50mg èèªé žãããªãŠã å¡© 60mg ãŠã€ãããŸãŒã« 1890mg 2000mg âã¹ã«ããªã³åå€ ã¹ã«ããªã³ 100mg èèªé žãããªãŠã å¡© 36mg ãŠã€ãããŸãŒã« 1064mg 1200mg
ãè¡šã
ãè¡šã
å®æœäŸ ïŒ
ïŒè©Šæã®èª¿è£œïŒ
ãŠã€ãããŸãŒã«ïŒšâïŒïŒãã€ããã€ãããŒãã«
瀟補ïŒ8.25ïœãã40â以äžã§æº¶è§£ããã®ã¡ã100
ã¡ãã·ãŠã®ç¯©ãééããã«ããªã³é žãããªãŠã
0.50ïœãå ããããæ¹æããŠåäžã«åæ£ãããŠåº
å€ãåŸãã次ã«ã100ã¡ãã·ãŠã®ç¯©ãééããã»
ãããã·ã 1.25ïœå䟡ãåœè©²åºå€ã«å ããŠåäžã«
åæ£ãããããããåå€çšã³ã³ããã«ïŒïœããŠå
å¡«ããŠæåããèéåå€ãšããã äžèšã®æ¹æ³ã«æºããŠè¡šïŒã®è©Šææ¬ã«èšèŒããåº
å€ããã³ä¿é²å€ïŒåçš®çé¢æŽ»æ§å€ïŒãããªãåºå€
ãåŸããããã«ããã«è¬ç掻æ§ç©è³ªæ¬ã«èšèŒãã
è¬å€ãåäžã«åæ£ããŠèéåå€ãåŸãã ïŒæž¬å®æ¹æ³ïŒ 24æé絶é£ããã€ãã®èéããçŽïŒcmã®æ·±éšã«
èéåå€ãæäžããã å°¿äžææ³éã®æž¬å®ã¯ãæäžåŸçµæçã«æ¡å°¿ãã
é©å®åžéããŠãçç©åŠçæ€å®æ³ã«ãã€ãŠåè¬ç掻
æ§ç©è³ªã®ïŒãïŒæéãŸã§ã®å°¿äžææ³éã枬å®ã
ãã çç©åŠçæ€å®ã¯ãæ€å®èãšããŠãããã©ã·ãªã³
ããã³ã»ããªãã©ãžã³ã«ã¯ã·ãŠãŠãã¢ãã¹ ã¢ãš
ã«ã®ããŒãµïŒP.aeruginosa NCTC 10490ïŒããã
以å€ã«ã¯ããã«ã¹ ãºãããªã¹ïŒB.subtilis
ATCC 6633ïŒãçšããããŒããŒãã€ã¹ã¯æ³ã§è¡
ã€ãããã®çµæã第ïŒè¡šã«ç€ºãã ãªããè¡šïŒã®å°¿äžææ³éã¯ãæäžéã«å¯Ÿããã
ãŒã»ã³ãã§ããããŸããè¡šäžã®ãPOEãã¯ãã
ãªãªãã·ãšãã¬ã³ãããPOPOEãã¯ãããªãªã
ã·ãããã¬ã³ã»ãªãã·ãšãã¬ã³ããæå³ããã ãã®çµæããæãããªããã«ãæ¬é¡çºæã§äœ¿çš
ãããççŽ æ°ïŒã12ã®èèªé žã®éæ¯æ§å¡©ã¯ãæ¯èŒ
ããåçš®çé¢æŽ»æ§å€ã«æ¯ã¹ãŠã極ããŠåªããå¹æ
ã瀺ããã®ã§ããã
瀟補ïŒ8.25ïœãã40â以äžã§æº¶è§£ããã®ã¡ã100
ã¡ãã·ãŠã®ç¯©ãééããã«ããªã³é žãããªãŠã
0.50ïœãå ããããæ¹æããŠåäžã«åæ£ãããŠåº
å€ãåŸãã次ã«ã100ã¡ãã·ãŠã®ç¯©ãééããã»
ãããã·ã 1.25ïœå䟡ãåœè©²åºå€ã«å ããŠåäžã«
åæ£ãããããããåå€çšã³ã³ããã«ïŒïœããŠå
å¡«ããŠæåããèéåå€ãšããã äžèšã®æ¹æ³ã«æºããŠè¡šïŒã®è©Šææ¬ã«èšèŒããåº
å€ããã³ä¿é²å€ïŒåçš®çé¢æŽ»æ§å€ïŒãããªãåºå€
ãåŸããããã«ããã«è¬ç掻æ§ç©è³ªæ¬ã«èšèŒãã
è¬å€ãåäžã«åæ£ããŠèéåå€ãåŸãã ïŒæž¬å®æ¹æ³ïŒ 24æé絶é£ããã€ãã®èéããçŽïŒcmã®æ·±éšã«
èéåå€ãæäžããã å°¿äžææ³éã®æž¬å®ã¯ãæäžåŸçµæçã«æ¡å°¿ãã
é©å®åžéããŠãçç©åŠçæ€å®æ³ã«ãã€ãŠåè¬ç掻
æ§ç©è³ªã®ïŒãïŒæéãŸã§ã®å°¿äžææ³éã枬å®ã
ãã çç©åŠçæ€å®ã¯ãæ€å®èãšããŠãããã©ã·ãªã³
ããã³ã»ããªãã©ãžã³ã«ã¯ã·ãŠãŠãã¢ãã¹ ã¢ãš
ã«ã®ããŒãµïŒP.aeruginosa NCTC 10490ïŒããã
以å€ã«ã¯ããã«ã¹ ãºãããªã¹ïŒB.subtilis
ATCC 6633ïŒãçšããããŒããŒãã€ã¹ã¯æ³ã§è¡
ã€ãããã®çµæã第ïŒè¡šã«ç€ºãã ãªããè¡šïŒã®å°¿äžææ³éã¯ãæäžéã«å¯Ÿããã
ãŒã»ã³ãã§ããããŸããè¡šäžã®ãPOEãã¯ãã
ãªãªãã·ãšãã¬ã³ãããPOPOEãã¯ãããªãªã
ã·ãããã¬ã³ã»ãªãã·ãšãã¬ã³ããæå³ããã ãã®çµæããæãããªããã«ãæ¬é¡çºæã§äœ¿çš
ãããççŽ æ°ïŒã12ã®èèªé žã®éæ¯æ§å¡©ã¯ãæ¯èŒ
ããåçš®çé¢æŽ»æ§å€ã«æ¯ã¹ãŠã極ããŠåªããå¹æ
ã瀺ããã®ã§ããã
ãè¡šã
ãè¡šã
ãè¡šã
å®æœäŸ ïŒ
ã«ããªã³é
žãããªãŠã ã®çŽè
žç²èã«å¯Ÿããå±æ
åºæ¿ã»é害æ§è©Šéš ïŒè©Šéšæ¹æ³ïŒ è©ŠæïŒãŠã€ãããŸãŒã«çŸ€ ãŠã€ãããŸãŒã«ïŒšâïŒã®ã¿ã®1.25ïœåå€ã«ã
ãªã³é žãããªãŠã ïŒCAâNaïŒçŸ€ä¹³ç³ãAMâ
Na250mgå䟡ã«çžåœããééããã³CAâNa25
mgããŠã€ãããŸãŒã«ïŒšâïŒã«æ··åããå šé1.25
ïœãšããåå€ åç©ããã³åç©æ°ïŒããŒã°ã«ç¬ ãŠã€ãããŸãŒã«çŸ€ âŠâŠïŒå¹ CAâNa矀 âŠâŠïŒå¹ æäžæ¹æ³ïŒ äžèšåå€ãïŒåïŒåãïŒæ¥ïŒåïŒïŒæéé
éïŒã§ïŒé±éé£ç¶çŽè žå æäžããã 芳å¯é ç®ïŒ ïŒé±éæäžåŸãäžè¬çç¶ãé£äŸ¿ã»äžç¢ãè
éã»çŽè žã®èçŒç芳å¯ãã³çŽè žç²èã®ç ççµç¹
åŠçæ€æ»ãè¡ããå矀ã®çµæãè¡šïŒã«ç€ºããã
åºæ¿ã»é害æ§è©Šéš ïŒè©Šéšæ¹æ³ïŒ è©ŠæïŒãŠã€ãããŸãŒã«çŸ€ ãŠã€ãããŸãŒã«ïŒšâïŒã®ã¿ã®1.25ïœåå€ã«ã
ãªã³é žãããªãŠã ïŒCAâNaïŒçŸ€ä¹³ç³ãAMâ
Na250mgå䟡ã«çžåœããééããã³CAâNa25
mgããŠã€ãããŸãŒã«ïŒšâïŒã«æ··åããå šé1.25
ïœãšããåå€ åç©ããã³åç©æ°ïŒããŒã°ã«ç¬ ãŠã€ãããŸãŒã«çŸ€ âŠâŠïŒå¹ CAâNa矀 âŠâŠïŒå¹ æäžæ¹æ³ïŒ äžèšåå€ãïŒåïŒåãïŒæ¥ïŒåïŒïŒæéé
éïŒã§ïŒé±éé£ç¶çŽè žå æäžããã 芳å¯é ç®ïŒ ïŒé±éæäžåŸãäžè¬çç¶ãé£äŸ¿ã»äžç¢ãè
éã»çŽè žã®èçŒç芳å¯ãã³çŽè žç²èã®ç ççµç¹
åŠçæ€æ»ãè¡ããå矀ã®çµæãè¡šïŒã«ç€ºããã
ãè¡šã
å®æœäŸ ïŒ
åå€ã®èª¿è£œ
æ²¹èæ§åå€åºå€ãŠã€ãããŸãŒã«ïŒšâïŒãçŽ50â
ã§çèããç·éã1.5ïœãšãªãããã«ãã®çèåº
å€ãåããããã«åçš®ã«ã«ãã³é žé¡ãŸãã¯ãã®ã
ããªãŠã å¡©400ÎŒã¢ã«ãšã¢ã³ãã·ãªã³ãããªãŠã
ïŒAMâNaïŒ250mgå䟡ãå ããåŸããæ¹æããã
ãããéå±ã®é³åã«å ¥ããŠååãããåå€ãäœè£œ
ããã ãªããïŒåã®åå€ééã¯AMâNaãšããŠã®æäž
éã12.5mgïŒKgãšãªãããã«äœè£œããã 枬å®æ¹æ³ å®éšåç©ãšããŠããŠã€ã¹ã¿ãŒç³»éæ§ã©ããïŒäœ
é170ã230ïœïŒãäžå€çµ¶é£ããŠäœ¿çšããããªãã
æ°Žã¯èªç±ã«æåããããAMâNaã12.5mgå䟡ïŒ
Kgã®æäžéã§åå€ãšããŠçŽè žæäžããæäžçŽåŸã«
è¬å€ã®æŒåºãé²ããããå€ç§çšæ¥çã¢ãã³ã¢ã«ã
ã¢ïŒç»é²åæšïŒãçšããŠèééšããµããã ãçè
å æäžã®å Žåã¯ãAMâNaã泚å°çšèžæºæ°Žã«æº¶è§£
ãã12.5mgå䟡ïŒKgæäžãããæ¡è¡ã¯è¬å€æäž
åŸãé éèããçµæçã«è¡ã€ããè¡äžã®AMâNa
æ¿åºŠããæ€å®èãšããŠMicrococcus luteus
ATCC 9341ãçšããã«ããæ³ã«ãã枬å®ããã ãã®çµæã¯ãè¡šïŒããã³ç¬¬ïŒå³ã®éãã§ããã
ã§çèããç·éã1.5ïœãšãªãããã«ãã®çèåº
å€ãåããããã«åçš®ã«ã«ãã³é žé¡ãŸãã¯ãã®ã
ããªãŠã å¡©400ÎŒã¢ã«ãšã¢ã³ãã·ãªã³ãããªãŠã
ïŒAMâNaïŒ250mgå䟡ãå ããåŸããæ¹æããã
ãããéå±ã®é³åã«å ¥ããŠååãããåå€ãäœè£œ
ããã ãªããïŒåã®åå€ééã¯AMâNaãšããŠã®æäž
éã12.5mgïŒKgãšãªãããã«äœè£œããã 枬å®æ¹æ³ å®éšåç©ãšããŠããŠã€ã¹ã¿ãŒç³»éæ§ã©ããïŒäœ
é170ã230ïœïŒãäžå€çµ¶é£ããŠäœ¿çšããããªãã
æ°Žã¯èªç±ã«æåããããAMâNaã12.5mgå䟡ïŒ
Kgã®æäžéã§åå€ãšããŠçŽè žæäžããæäžçŽåŸã«
è¬å€ã®æŒåºãé²ããããå€ç§çšæ¥çã¢ãã³ã¢ã«ã
ã¢ïŒç»é²åæšïŒãçšããŠèééšããµããã ãçè
å æäžã®å Žåã¯ãAMâNaã泚å°çšèžæºæ°Žã«æº¶è§£
ãã12.5mgå䟡ïŒKgæäžãããæ¡è¡ã¯è¬å€æäž
åŸãé éèããçµæçã«è¡ã€ããè¡äžã®AMâNa
æ¿åºŠããæ€å®èãšããŠMicrococcus luteus
ATCC 9341ãçšããã«ããæ³ã«ãã枬å®ããã ãã®çµæã¯ãè¡šïŒããã³ç¬¬ïŒå³ã®éãã§ããã
ãè¡šã
ãè¡šã
ãã®çµæãããèèªé
žå¡©ã®äžã§ããæ¬é¡çºæã§
䜿çšãããççŽ æ°ïŒã12ã®ãã®ã¯ãããããççŽ
æ°ã®å°ãªããã®ããã³å€ããã®ã«æ¯ã¹ãŠã極ããŠ
åªããå¹æã瀺ããã®ã§ããããšãæããã§ã
ãã å®æœäŸ 10 ã©ããã®çŽè žãã«ããªã³é žãããªãŠã ã®0.5ïŒ
ç·©è¡æ¶²ïŒPH7.4ã289mOsmïŒã§10åééæµããã€
ãã§ççé£å¡©æ¶²ïŒPH7.4ã289mOsmïŒã§ïŒåéé
æµããåŸã2.5ïŒ ã¢ã³ãã·ãªã³Na塩溶液ïŒPH7.4ã
289mOsmïŒãéæµããã¢ã³ãã·ãªã³Naå¡©ã®è¡äž
æ¿åºŠãçµæçã«æž¬å®ãããã®çµæã第ïŒå³ã«ç€ºã
ãã 第ïŒå³äžãââ¡âã¯æ¬çºæã§ãããââ²âã¯2.5
ïŒ ã¢ã³ãã·ãªã³Na塩溶液ã®ã¿ãéæµãããã®ã§
ããã
䜿çšãããççŽ æ°ïŒã12ã®ãã®ã¯ãããããççŽ
æ°ã®å°ãªããã®ããã³å€ããã®ã«æ¯ã¹ãŠã極ããŠ
åªããå¹æã瀺ããã®ã§ããããšãæããã§ã
ãã å®æœäŸ 10 ã©ããã®çŽè žãã«ããªã³é žãããªãŠã ã®0.5ïŒ
ç·©è¡æ¶²ïŒPH7.4ã289mOsmïŒã§10åééæµããã€
ãã§ççé£å¡©æ¶²ïŒPH7.4ã289mOsmïŒã§ïŒåéé
æµããåŸã2.5ïŒ ã¢ã³ãã·ãªã³Na塩溶液ïŒPH7.4ã
289mOsmïŒãéæµããã¢ã³ãã·ãªã³Naå¡©ã®è¡äž
æ¿åºŠãçµæçã«æž¬å®ãããã®çµæã第ïŒå³ã«ç€ºã
ãã 第ïŒå³äžãââ¡âã¯æ¬çºæã§ãããââ²âã¯2.5
ïŒ ã¢ã³ãã·ãªã³Na塩溶液ã®ã¿ãéæµãããã®ã§
ããã
第ïŒå³ããã³ç¬¬ïŒå³ã¯åçš®èèªé
žå¡©ã®ãè¬ç掻
æ§ç©è³ªã«å¯Ÿããè¡äžãžã®åžåä¿é²å¹æã瀺ããã°
ã©ãã§ããã第ïŒå³ã¯èèªé žã¢ã«ã«ãªéå±å¡©æäž
åŸã«ããããæŽãæµããåŸã«ãããè¬ç掻æ§ç©è³ª
ã®è¡äžãžã®åžåä¿é²å¹æã瀺ããã°ã©ãã§ããã
æ§ç©è³ªã«å¯Ÿããè¡äžãžã®åžåä¿é²å¹æã瀺ããã°
ã©ãã§ããã第ïŒå³ã¯èèªé žã¢ã«ã«ãªéå±å¡©æäž
åŸã«ããããæŽãæµããåŸã«ãããè¬ç掻æ§ç©è³ª
ã®è¡äžãžã®åžåä¿é²å¹æã瀺ããã°ã©ãã§ããã
Claims (1)
- ãç¹èš±è«æ±ã®ç¯å²ã ïŒ ççŽ æ°ïŒä¹è³12ã®èèªé žã®ã¢ã«ã«ãªéå±å¡©ã
æ²¹æ§åºå€äžã«åæ£ç¶æ ã§å«æãããŠãªãããšãç¹
城ãšããéãã»ã«åçŽè žæäžçšçµæç©ã ïŒ èèªé žã®ã¢ã«ã«ãªéå±å¡©ãèèªé žã®ãããªãŠ
ã å¡©ã§ããããšãç¹åŸŽãšããç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒ
é èšèŒã®çŽè žæäžçšçµæç©ã ïŒ è¬ç掻æ§ç©è³ªãé åããŠãªãç¹èš±è«æ±ã®ç¯å²
第ïŒé ãŸãã¯ç¬¬ïŒé èšèŒã®çŽè žæäžçšçµæç©ã ïŒ è¬ç掻æ§ç©è³ªãβâã©ã¯ã¿ã ç°ãæããåå
ç©ãŸãã¯ã€ã³ã·ãŠãªã³ã§ããç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒ
é èšèŒã®çŽè žæäžçšçµæç©ã
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP5769079A JPS55149209A (en) | 1979-05-10 | 1979-05-10 | Composition for rectal administration |
GB8015044A GB2051574B (en) | 1979-05-10 | 1980-05-06 | Adjuvant for promoting absorption of pharmacologically active substances through the rectum |
FR8010267A FR2455897A1 (fr) | 1979-05-10 | 1980-05-08 | Adjuvant du type acide gras pour favoriser l'absorption de substances pharmacologiquement actives par le rectum, composition de base pour administration rectale comprenant cet adjuvant et composition pharmaceutique comprenant cet adjuvant |
DE19803017829 DE3017829A1 (de) | 1979-05-10 | 1980-05-09 | Adjuvans zur foerderung der rektalen absorption von pharmazeutischen wirkstoffen und dieses adjuvans enthaltende mittel |
US06/149,132 US4338306A (en) | 1979-05-10 | 1980-05-12 | Adjuvant for promoting absorption of pharmacologically active substances through the rectum |
CA000364040A CA1166964A (en) | 1979-05-10 | 1980-11-05 | Adjuvant for promoting absorption of pharmacologically active substances through the rectum, rectal base composition comprising said adjuvant and pharmaceutical composition comprising said adjuvant |
US06/365,021 US4485033A (en) | 1979-05-10 | 1982-04-02 | Adjuvant for promoting absorption of pharmacologically active substances through the rectum |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP5769079A JPS55149209A (en) | 1979-05-10 | 1979-05-10 | Composition for rectal administration |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP18398684A Division JPS60149519A (ja) | 1984-09-03 | 1984-09-03 | çŽè žæäžçšçµæç© |
Publications (2)
Publication Number | Publication Date |
---|---|
JPS55149209A JPS55149209A (en) | 1980-11-20 |
JPS6256128B2 true JPS6256128B2 (ja) | 1987-11-24 |
Family
ID=13062932
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP5769079A Granted JPS55149209A (en) | 1979-05-10 | 1979-05-10 | Composition for rectal administration |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPS55149209A (ja) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0637397B2 (ja) * | 1985-02-07 | 1994-05-18 | æåæå·¥æ¥æ ªåŒäŒç€Ÿ | ã«ã«ã·ããã³é¡ã®çŽè žæäžçšçµæç© |
JPS61289033A (ja) * | 1985-06-17 | 1986-12-19 | Taiho Yakuhin Kogyo Kk | ãŠã©ã·ã«åã³ïŒâãã«ãªããŠã©ã·ã«ã®çŽè žæäžçšè£œå€ |
JPS6284018A (ja) * | 1985-10-09 | 1987-04-17 | Kao Corp | åå€ |
JPH0816051B2 (ja) * | 1988-12-07 | 1996-02-21 | ãšã¹ãšã¹è£œè¬æ ªåŒäŒç€Ÿ | åŸæŸæ§åå€ |
DE4134831C2 (de) * | 1991-10-22 | 1995-05-18 | Mannesmann Ag | Anordnung zur Ermittlung einer Reibbeiwert-Information |
WO1993008804A1 (en) * | 1991-11-08 | 1993-05-13 | Kyoto Pharmaceutical Industries, Ltd. | Pharmaceutical preparation containing prostaglandin compound for rectal or vaginal administration |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5082221A (ja) * | 1973-11-08 | 1975-07-03 | ||
JPS5261217A (en) * | 1975-11-11 | 1977-05-20 | Toyama Chem Co Ltd | Method for increasing absorption of novel penicillin at rectal infusio n |
JPS5272812A (en) * | 1975-12-12 | 1977-06-17 | Banyu Pharmaceut Co Ltd | Preparation of cephatridin pharmaceuticals for rectal infusion |
JPS54160713A (en) * | 1978-06-05 | 1979-12-19 | Kali Chemie Pharma Gmbh | Medical preparation with improved absorbability and production |
-
1979
- 1979-05-10 JP JP5769079A patent/JPS55149209A/ja active Granted
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5082221A (ja) * | 1973-11-08 | 1975-07-03 | ||
JPS5261217A (en) * | 1975-11-11 | 1977-05-20 | Toyama Chem Co Ltd | Method for increasing absorption of novel penicillin at rectal infusio n |
JPS5272812A (en) * | 1975-12-12 | 1977-06-17 | Banyu Pharmaceut Co Ltd | Preparation of cephatridin pharmaceuticals for rectal infusion |
JPS54160713A (en) * | 1978-06-05 | 1979-12-19 | Kali Chemie Pharma Gmbh | Medical preparation with improved absorbability and production |
Also Published As
Publication number | Publication date |
---|---|
JPS55149209A (en) | 1980-11-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US4485033A (en) | Adjuvant for promoting absorption of pharmacologically active substances through the rectum | |
US5190748A (en) | Absorption enhancement of antibiotics | |
EP1841432B1 (en) | Compositions for combating beta-lactamase-mediated antibiotic resistance using beta-lactamase inhibitors useful for injection | |
KR19990022220A (ko) | ìë£ ì©ëì 믞ì-캡ìíë ëœí ë°ì€ë¬ì€ | |
US20130310372A1 (en) | Pharmaceutical transdermal compositions and method for treating inflammation in cattle | |
AU625276B2 (en) | Pharmaceutical compositions | |
JPS6256128B2 (ja) | ||
JP2006510607A (ja) | æç¶æŸåºæ§å»è¬çµæç© | |
AU2002348256B2 (en) | Antibiotic formulation and a method of making this formulation | |
CA2416566C (en) | Depot formulation comprising ceftiofur and peroxidized natural oil | |
JPS6396138A (ja) | 補è¬åŠççµæç© | |
JPS5857407B2 (ja) | çŽè žæäžå€çšåºå€ | |
JPS6055486B2 (ja) | βâã©ã¯ã¿ã ç°ãæããååç©ã®çŽè žæäžçšçµæç© | |
JPS60149519A (ja) | çŽè žæäžçšçµæç© | |
Tan et al. | Bacampicillin, ampicillin, cephalothin, and cephapirin levels in human blood and interstitial fluid | |
JPS6245521A (ja) | æ²¹æ§æžæ¿åçŽè žæ³šå ¥å€ | |
JPH0637397B2 (ja) | ã«ã«ã·ããã³é¡ã®çŽè žæäžçšçµæç© | |
CA1157377A (en) | Pharmaceutical preparations for rectal administration, and the production and suppository base thereof | |
JPH03106827A (ja) | è¬åŠççµæç© | |
HU195732B (en) | Procecc for the production of medical composition applicable for rectal dosage | |
JPS6067413A (ja) | çŽè žæäžçšçµæç© | |
JPH09323934A (ja) | ä¿åå®å®æ§ã®æ¹åãããåå€ | |
EP0339176A1 (en) | Suppository containing a non-steroidal anti-inflammatory medicament | |
JPS5921612A (ja) | βâã©ã¯ã¿ã ç°ãæããååç©ã®çŽè žæäžçšçµæç© | |
KR820002224B1 (ko) | ìžíë¡ì€í¬ëŠ°ì ì§ì¥ í¬ì¬ì© ììœ ì¡°ì±ë¬Œì ì ì¡° ë°©ë² |